MedPath

Evaluation Study of SPOTme® Skin Cancer Screenings

Not Applicable
Completed
Conditions
Skin Cancer
Interventions
Behavioral: Intervention Arm
Other: AAD SPOTmeⓇ skin cancer screening
Registration Number
NCT03564769
Lead Sponsor
Harvard School of Public Health (HSPH)
Brief Summary

This study evaluates the impact of the AAD SPOTme® skin cancer screening events on attendees' skin cancer prevention and detection behaviors. This study will also evaluate whether an educational intervention will improve post-screening engagement of attendees with dermatologists.

Detailed Description

Despite tremendous growth in both the interest and volume of skin cancer screenings at the national level, the actual utility and impact of the AAD SPOT me™ skin cancer screening programs have not been fully evaluated. This study will address this knowledge gap. Early detection is vital in the fight against skin cancer, the most common cancer in the United States. While the effects of skin cancer can be devastating, this disease is highly treatable when detected early.

This study evaluates the impact of the AAD SPOTme® skin cancer screening events on attendees' skin cancer prevention and detection behaviors. This study will also evaluate whether an educational intervention will improve post-screening engagement of attendees with dermatologists.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
431
Inclusion Criteria
  • Participated in the American Academy of Dermatology national screening program in 2016 or 2017
  • Have a presumptive diagnosis (screening, non-confirmed) of melanoma
  • Have provided the AAD with permission to be re-contacted
  • Have provided the AAD with an email address
  • Aged 18 years or older
  • Able to read English
Exclusion Criteria
  • None

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Intervention Arm 1Intervention ArmIndividuals randomized to intervention group 1 will have participated in the AAD SPOTmeⓇ skin cancer screening program in either 2016 or 2017 AND will receive additional skin cancer screening educational materials.
Intervention Arm 1AAD SPOTmeⓇ skin cancer screeningIndividuals randomized to intervention group 1 will have participated in the AAD SPOTmeⓇ skin cancer screening program in either 2016 or 2017 AND will receive additional skin cancer screening educational materials.
Intervention Arm 2AAD SPOTmeⓇ skin cancer screeningIndividuals randomized to intervention group 2 will have participated in the AAD SPOTmeⓇ skin cancer screening program in either 2016 or 2017 only.
Primary Outcome Measures
NameTimeMethod
Completion of a physician skin examinationBaseline

Self-report of a physician skin examination will be defined as a health care provider examining the patient's entire body for any sign of skin cancer during the period following patient's receipt of an AAD SPOTme® skin cancer screening to the baseline assessment.

Secondary Outcome Measures
NameTimeMethod
Patient thorough skin self-examination (TSSE)6 months

Self-report of patient thorough skin self-examination (TSSE) will be defined as performing at least one TSSE during the 3 months prior to the 6-month follow up assessment

Completion of a physician skin examination6 months

Self-report of a physician skin examination will be defined as a health care provider examining the patient's entire body for any sign of skin cancer during the 3 months prior to the 6-month follow up assessment

Patient attitude towards sun protection6 months

Self-report of patient attitude towards use of sun protection will be defined by likelihood of engaging in sun protection practices in the year following the 6-month follow up assessment

Trial Locations

Locations (1)

Harvard TH Chan School of Public Health

🇺🇸

Boston, Massachusetts, United States

© Copyright 2025. All Rights Reserved by MedPath